Astrana Health, Inc.
Astrana Health, Inc. Fundamental Analysis
Astrana Health, Inc. (ASTH) shows weak financial fundamentals with a PE ratio of 102.97, profit margin of 0.33%, and ROE of 1.27%. The company generates $3.0B in annual revenue with strong year-over-year growth of 46.72%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 37.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze ASTH's fundamental strength across five key dimensions:
Efficiency Score
WeakASTH struggles to generate sufficient returns from assets.
Valuation Score
ModerateASTH shows balanced valuation metrics.
Growth Score
ModerateASTH shows steady but slowing expansion.
Financial Health Score
ModerateASTH shows balanced financial health with some risks.
Profitability Score
ModerateASTH maintains healthy but balanced margins.
Key Financial Metrics
Is ASTH Expensive or Cheap?
P/E Ratio
ASTH trades at 102.97 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ASTH's PEG of -1.65 indicates potential undervaluation.
Price to Book
The market values Astrana Health, Inc. at 1.27 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.48 times EBITDA. This is generally considered low.
How Well Does ASTH Make Money?
Net Profit Margin
For every $100 in sales, Astrana Health, Inc. keeps $0.33 as profit after all expenses.
Operating Margin
Core operations generate 2.10 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.27 in profit for every $100 of shareholder equity.
ROA
Astrana Health, Inc. generates $0.43 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Astrana Health, Inc. generates limited operating cash flow of $108.63M, signaling weaker underlying cash strength.
Free Cash Flow
Astrana Health, Inc. produces free cash flow of $98.87M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $1.97 in free cash annually.
FCF Yield
ASTH converts 9.69% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
102.97
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.65
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.27
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.35
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.40
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.40
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.004
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How ASTH Stacks Against Its Sector Peers
| Metric | ASTH Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 102.97 | 29.45 | Worse (Expensive) |
| ROE | 1.27% | 779.00% | Weak |
| Net Margin | 0.33% | -24936.00% (disorted) | Weak |
| Debt/Equity | 1.40 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.40 | 4.65 | Neutral |
| ROA | 0.43% | -19344.00% (disorted) | Weak |
ASTH outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Astrana Health, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
164.14%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
122.47%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
173.06%
Industry Style: Defensive, Growth, Innovation
High Growth